Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Burkholderia phytofirmans UDP-N-acetylglucosamine 1-carboxyvinyltransferase (murA) CSB-YP460601BXU
CSB-EP460601BXU
CSB-BP460601BXU
CSB-MP460601BXU
CSB-EP460601BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans Alanine--tRNA ligase (alaS), partial CSB-YP460602BXU
CSB-EP460602BXU
CSB-BP460602BXU
CSB-MP460602BXU
CSB-EP460602BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 60 kDa chaperonin (groL), partial CSB-YP460603BXU
CSB-EP460603BXU
CSB-BP460603BXU
CSB-MP460603BXU
CSB-EP460603BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans Deoxycytidine triphosphate deaminase (dcd) CSB-YP460604BXU
CSB-EP460604BXU
CSB-BP460604BXU
CSB-MP460604BXU
CSB-EP460604BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans NADH-quinone oxidoreductase subunit K (nuoK), partial CSB-YP460605BXU1
CSB-EP460605BXU1
CSB-BP460605BXU1
CSB-MP460605BXU1
CSB-EP460605BXU1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans Glucose-1-phosphate adenylyltransferase (glgC) CSB-YP460606BXU
CSB-EP460606BXU
CSB-BP460606BXU
CSB-MP460606BXU
CSB-EP460606BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans Adenylyl-sulfate kinase (cysC) CSB-YP460607BXU
CSB-EP460607BXU
CSB-BP460607BXU
CSB-MP460607BXU
CSB-EP460607BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 50S ribosomal protein L31 type B (rpmE2) CSB-YP460608BXU
CSB-EP460608BXU
CSB-BP460608BXU
CSB-MP460608BXU
CSB-EP460608BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase (ispD) CSB-YP460609BXU
CSB-EP460609BXU
CSB-BP460609BXU
CSB-MP460609BXU
CSB-EP460609BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans UPF0061 protein Bphyt_1924 (Bphyt_1924), partial CSB-YP460610BXU
CSB-EP460610BXU
CSB-BP460610BXU
CSB-MP460610BXU
CSB-EP460610BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans Acyl-[acyl-carrier-protein]--UDP-N-acetylglucosamine O-acyltransferase (lpxA) CSB-YP460611BXU
CSB-EP460611BXU
CSB-BP460611BXU
CSB-MP460611BXU
CSB-EP460611BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans DNA ligase (ligA), partial CSB-YP460612BXU
CSB-EP460612BXU
CSB-BP460612BXU
CSB-MP460612BXU
CSB-EP460612BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans Phosphate acyltransferase (plsX) CSB-YP460613BXU
CSB-EP460613BXU
CSB-BP460613BXU
CSB-MP460613BXU
CSB-EP460613BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans ADP-L-glycero-D-manno-heptose-6-epimerase (hldD) CSB-YP460614BXU
CSB-EP460614BXU
CSB-BP460614BXU
CSB-MP460614BXU
CSB-EP460614BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 3-demethylubiquinone-9 3-methyltransferase (ubiG) CSB-YP460615BXU
CSB-EP460615BXU
CSB-BP460615BXU
CSB-MP460615BXU
CSB-EP460615BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans Isoleucine--tRNA ligase (ileS), partial CSB-YP460616BXU
CSB-EP460616BXU
CSB-BP460616BXU
CSB-MP460616BXU
CSB-EP460616BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans tRNA 2-thiocytidine biosynthesis protein TtcA (ttcA) CSB-YP460617BXU
CSB-EP460617BXU
CSB-BP460617BXU
CSB-MP460617BXU
CSB-EP460617BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 50S ribosomal protein L18 (rplR) CSB-YP460618BXU
CSB-EP460618BXU
CSB-BP460618BXU
CSB-MP460618BXU
CSB-EP460618BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans 50S ribosomal protein L23 (rplW) CSB-YP460619BXU
CSB-EP460619BXU
CSB-BP460619BXU
CSB-MP460619BXU
CSB-EP460619BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Burkholderia phytofirmans DNA-directed RNA polymerase subunit beta (rpoB), partial CSB-YP460620BXU
CSB-EP460620BXU
CSB-BP460620BXU
CSB-MP460620BXU
CSB-EP460620BXU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時,你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>